Clinical Trial: Plovamer acetate - National Multiple Sclerosis Society

Skip to navigation Skip to content

Clinical Trial: Plovamer acetate

Share

Details
Type of MS: RRMS
Treatment mode of action: To affect immune function, immunomodulating
Number of Subjects: 550
Location: CA|FL|GA|MA|MI|NY|NC|OH|PA|TX|VA|WA
Contact Information
EMD Serono US Medical Information
1-866-275-7376

Funding:

EMD Serono

Description

A phase II, randomized, multi-center, parallel-group, rater-blinded study to evaluate the efficacy, safety and tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg plovamer acetate doses compared to Copaxone in people with relapsing-remitting multiple sclerosis.

Share